Connect with us

Cannabis News

When we decided to start our own hydroponic farm, we were always open to the possibility of growing cannabis down the road

Published

3 months ago

on

Farm Girl Greens launched in Auburn, New York in late 2019 as a vertical hydroponic leafy greens operation supplying restaurants and farmers markets. The business remained profitable due to changing sales channels, fluctuating grant funding and rising energy costs, but the financial model was becoming increasingly difficult to predict.

When New York legalized adult cannabis and implemented a micro-business licensing structure, the regulatory landscape changed. The subsequent pivot was not sudden, according to co-owner Abby Lepak, but rather the activation of a long-considered opportunity. “When we decided to start our hydroponic farm, we were always open to growing cannabis,” he explains. “At the time, cannabis wasn’t legal in New York state, so our initial business plan was focused on leafy greens.”

© Green farm girls
Farm Girl Greens grow room showing off ZipGrow mobile tower trellis under LED lighting

Market volatility and margin pressure
The farm planted the first seeds in November 2019. By March 2020, the restaurant and farmers market channels had either closed or switched to takeout. “Running a business in the early 2020s was a challenge for any small business owner,” says Lepak. “We were successful in the beginning because of the grocery store supply chain and consumers wanting to buy directly from farmers.”

Farm Girl Greens focused on weekly home deliveries through a distributor as well as its own logistics. As restaurants reopened, sales shifted to food service accounts, reducing margins compared to direct-to-consumer channels. “It was profitable but not so predictable,” says Lepa about the green phase.

An additional outlet was operated by a non-profit nonprofit that supplied food pantries at retail prices by paying subsidies rather than consumers. “The food was free to the consumer, but the funding was unpredictable and then dwindled.”
Utility costs added further pressure. Rising energy bills prompted the farm to build a grant-funded solar installation. The system remains in effect today. “New York state is seeing energy costs double from one month to the next right now,” Lepak says. “Not just for companies.” Profitable but subject to fluctuating demand, unstable funding streams and rising operating costs, the green model became more difficult to plan.

© Green farm girls

A microenterprise license changes the model
Legalization introduced another option. Farm Girl Greens obtained a Micro Business License from the Office of Cannabis Management, New York’s governing body for adult cannabis. “The emerging market of adult-use cannabis cultivation has a bright future,” says Lepak. “The Bureau of Cannabis Management has taken steps to prevent large growers from flooding the market. Because we are a small grower and a predominantly female-owned business, we have been able to take advantage of training and fees at reduced prices and sometimes at no cost.”

The license allows cultivation, processing, distribution and retailing under one structure. For now, the farm is cultivating and shaking the flowers, using a third-party processor to extract them, and selling wholesale to pharmacies. As an indoor micro-business, the production covers 3,500 square feet of space and processes 1,700 pounds of cannabis per year.

Different crop, different system
Change required new infrastructure. The ZipGrow tower system used for leafy greens has been replaced with a high-pressure aeroponic recirculation system designed by Current Culture, along with a vertical rack from Pipp Horticulture.

“The leafy greens in our ZipGrow system didn’t require as much space and had a shorter seed-to-harvest cycle,” says Lepak. At peak production, the farm harvested the equivalent of 1,500 heads of lettuce per week while planting another 1,500 seeds.

Indoor cannabis works on a longer cycle, usually between 90 and 100 days. With a flower room currently in operation, the farm expects five harvests a year at full production. A second flower room is planned. Once built, a staggered planting schedule would allow ten harvests per year.

© Green farm girls

Higher margins, higher limits
Per square foot, cannabis offers stronger margins than leafy greens, Lepak says. But regulatory costs and add-ons dampen this advantage. “We expect margins to increase as cannabis legalization and additional fees decrease. These fees are very close to being cost prohibitive.”

Compliance-related packaging requirements and limited access to banking continue to weigh on profitability. Job applications have also changed. Leafy greens required a steady weekly workforce to manage the cycles and distribution of perishable crops. Growing cannabis involves less daily handling, but requires more concentrated work during the harvest and processing periods.

© Green farm girls
A member of the Farm Girl Greens team transplants seedlings (left) and inside a Matrix Media ZipGrow tower channel (right)

Looking back
Despite the transition, Lepa says he would still start with green leaves. “I enjoyed learning the process of indoor growing and selling at farmers markets,” she says. “Being a grower that delivers product directly to a consumer was a joy for me.”

Farm Girl Greens is selling its ZipGrow tower inventory as it consolidates its cannabis growing operations. “We have a total of 630 towers and associated lights and are willing to sell 450 towers, 180 towers or all 630 together,” says Lepak. “The eight-foot towers are mounted in 21 racks of 30 units. Complete system purchase of all 630 towers includes additional climate control equipment at no additional cost: CO2 generator and vertical V-Flow fans.”

Those interested in buying towers can go directly to Lepak (email protected).


A video tour of the Farm Girl Greens farm setup

© Green farm girls
Complete design of the ZipGrow tower system inside the farm

For more information:
Green Farm Girls
Abby Lepak, co-owner
(email protected)
www.instagram.com/farmgirlgreens

Related Topics:
Continue Reading

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

11 hours ago

on

June 8, 2026

By











Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/










Continue Reading

Cannabis News

Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State

Published

11 hours ago

on

June 8, 2026

By

“Congratulations to President Trump for stepping up and taking the lead on this. PTSD is a killer among veterans.”

By Rebecca Rivas, Missouri Independent

Missouri state representative Dave Griffith has spent the past five years researching how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression.

His last legislative session in the House ended this May, and he pushed legislation for the last time allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of the session, the bill stalled in the Missouri Senate after passing the House with overwhelming support.

“I’m not going to be there next year, I’m term-limited,” said Griffith, a Republican who served as chairman of the House Veterans Affairs and Armed Services Committee. “It’s really about passing the torch to a lot of other veterans who are on the Veterans Commission and see the value in that.”

He was hopeful when he saw an announcement The US Department of Veterans Affairs announced last week a new clinical trial to evaluate the safety and effectiveness of methylenedioxymethamphetamine-assisted therapy.or MDMA-assisted therapy. MDMA is a synthetic substance made in a laboratory, according to the department, and is also called “ecstasy” or “molly” in recreational use.

“Congratulations to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is a killer among veterans. If you just listen to the testimony that’s been happening over the last five years in the Missouri House, the life-changing it’s been for them is a compelling reason why something like this works.”

A new trial follows Trump signed an executive order in April, “Expediting Medical Treatment for Serious Mental Illness.” The order aims to increase participation in clinical trials and accelerate innovative research models and drug approvals for psychedelics.

Directs the Secretary of Health and Human Services to allocate at least $50 million to support and collaborate with state governments that “have established or are developing programs to advance psychedelic drugs for serious mental illness.”

Without passing the legislation, Missouri will miss this opportunity, said Republican state representative Matthew Overcast of Ava.

Cloud hoped that Trump’s April order would help “grease the wheels” this year by state Rep. Richard West and state Rep. Richard West who sponsored the state to conduct a study on psilocybin and ibogaine therapy.

“The last couple of months there’s been a lot of feds on things that the states are reluctant to move forward with here,” Overcast said. “So it’s exciting.”

According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that have received more than $23 million in outside funding.

The new trial, called “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in US Veterans,” will enroll about 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving the same psychotherapy with an active placebo. VA is coordinating with the US Food and Drug Administration and plans to share trial data with FDA.

The trial will be conducted at the VA Providence Healthcare System, and will recruit veterans from the Providence, Rhode Island, campus in West Haven, Connecticut, and the VA Connecticut Healthcare System.

Trump’s executive order says there have been more than 6,000 veteran suicides per year for more than 20 years, and the current veteran suicide rate is twice that of the adult non-veteran population.

He says people with major depressive disorder and substance abuse disorder, among other serious mental illnesses, may relapse or fail to respond fully to standard medical and psychiatric therapies.

“Despite significant federal investment in research into potential advances in mental health care and treatment, our medical research system has yet to produce approved therapies that promote lasting improvements in the mental health status of the most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription drugs.”

Missouri veterans John and Kara Grady, who own a hemp shop in Rosebud, strongly agree with the statement, they said. And they’d like to see Missouri’s veterans health system participate in clinical trials already underway.

“President Trump is opening up investigations for the veteran community,” said John Grady, “If you look at the numbers … we’ve lost more in the wars with mental health than we’ve lost.”

The lack of movement on psychedelic-assisted therapy legislation is among the reasons why John Grady is running for state representative over Bruce Sassmann in the state’s Republican primary.

“If you don’t agree with Trump on everything, at least he’s addressing this veteran issue right here,” Grady said. “Hopefully, we’ll be able to stop that number, we’ll stop that flow of our precious veterans dying by their own hands because they don’t have treatment.”

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Germany’s medical cannabis imports post first quarterly decline since early 2024

Published

1 day ago

on

June 7, 2026

By

German imports of medical cannabis flowers fell to 50.5 tonnes in the first quarter of 2026, down from 60.8 tonnes in the previous quarter, the decline from the first quarter of 2024. According to a new EU and UK market update from Whitney Economics.

The drop lands against a year that went backwards. Germany took in more than 2025 tonnes of the product in 2025, more than double the 72,850 kilograms recorded in 2024, and import volumes have risen every year since 2018, when the figure remained below 4,500 kilograms. The first quarter number continues to match the high pace of 2025, which is why the report treats it as an early sign of stabilization rather than a turnaround.

Prices
The volume has not created a stable price. A gram of cannabis in a German pharmacy is approaching 4 euros, while a gram on the illegal market is around 8 euros, reversing the usual relationship between regulated and unregulated supply. The wholesale price is around 2 euros per gram, roughly half the retail price at the pharmacy. Pharmacy prices breached 3.99 euros in November 2025, and the report puts the overall compression close to 25% in two and a half years.

Germany legalized ownership in 2024 and restricted sales to pharmaceutical and telemedicine providers. Two access roads run parallel. Medical cannabis is mainly prescribed through private prescriptions, and recreational cannabis is available through membership of a cannabis association, with 400 licensed cultivation associations across the country, although the exact count varies by source. It is the medical segment that drives market growth, not the recreational segment.

Growth is based on telemedicine
 Patients fill out an online questionnaire, receive a prescription from an affiliated physician, and in many cases have their order filled through an integrated pharmacy partner, with delivery within days and, in some cities, within hours. Between 600,000 and 700,000 self-employed consumers are supported by the telemedicine industry, compared to 200,000 to 300,000 medical patients supported by pharmacies. Total imports are now sufficient to supply between 900,000 and one million consumers.

© Philiprowe | Dreamstime

Market exposure
Critics argue that commercial interests risk overshadowing the medical nature of the system, and treatment does not always meet the required standard of control. Legislative initiatives that would tighten the framework are already on the table, including mandatory in-person inquiries and a ban on distribution of mail requests. The likely result of both measures is a significant decline in demand for medical cannabis flowers. Many telemedicine companies are preparing for the opportunity by building networks with local doctors and pharmacies.

Where patients and consumers would go if medical access is curtailed is an open question, as the recreational market lacks a real alternative for patients and cannabis clubs continue to face licensing hurdles at the state level.

Part of the difficulty in reading the market is that import figures say less than they seem. More cannabis is entering the country than ever before, but how much is reaching consumers and what the actual demand is is unclear. Without a nationwide data framework, the market functions as a black box, and excess supply and actual demand are difficult to measure with great precision. Supply has tended to expand faster than the market can absorb, with no forecast to confirm mature demand, and prices have adjusted downward as a result.

Germany has had a signal effect across Europe since the start of its reform, although its model has drawn criticism, with the mixing of medical and recreational consumption a recurring complaint. Countries that have traditionally taken a conservative line, France among them, have gone to a more formalized medical field, under stricter conditions and without adopting the medical flower like Germany.

For more information:
Whitney Economics
Beau Whitney
(503) 724-3084
www.whitneyeconomics.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media